# Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

> **NCT02340936** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea** · enrollment: 53 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** LR-ESHAP (lenalidomide 5 mg)
- **DRUG:** LR-ESHAP (lenalidomide 10 mg)
- **DRUG:** LR-ESHAP (lenalidomide 15 mg)
- **DRUG:** LR-ESHAP (lenalidomide 20 mg)

## Key facts

- **NCT ID:** NCT02340936
- **Lead sponsor:** Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2016-09
- **Final completion:** 2019-02-20
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02340936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02340936, "Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02340936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*